You are here

Hormone Therapy Patch Approved for the Prevention of Postmenopausal Osteoporosis

Schering AG, Germany (FSE: SCH, NYSE: SHR) announced today that the Food and Drug Administration (FDA) has approved the hormone therapy patch, Climara Pro (estradiol/levonorgestrel transdermal system), for the prevention of postmenopausal osteoporosis in the U.S.

Climara Pro was approved by the FDA in November 2003 as a treatment for moderate to severe vasomotor symptoms such as hot flashes and night sweats associated with menopause. Climara Pro® is the only combination once-a-week patch approved for the prevention of postmenopausal osteoporosis and the relief of moderate to severe vasomotor symptoms associated with menopause.

“Climara Pro offers an innovative treatment option for menopausal symptoms and helps to maintain women’s health,” said Philip Smits, M.D., Head of Gynecology&Andrology at Schering AG. “The approval for osteoporosis prevention supports our position in the field of menopause management. Schering is committed to providing the best care in this field.”

The transdermal technology of Climara Pro® allows for week-long continuous delivery of the hormone estradiol (0.045 mg/day), the same estrogen made by the ovaries prior to menopause, combined with levonorgestrel (0.015 mg/day) which helps protect the endometrium. Climara Pro® delivers the hormones through a thin, translucent patch that is easily affixed to the skin and is virtually invisible after being applied.

Source: Schering AG

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs